Global Adalimumab (Humira) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Adalimumab (Humira) and Biosimilar market size was valued at USD 23070 million in 2022 and is forecast to a readjusted size of USD 16210 million by 2029 with a CAGR of -4.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report is a detailed and comprehensive analysis for global Adalimumab (Humira) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Adalimumab (Humira) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adalimumab (Humira) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Adalimumab (Humira) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Adalimumab (Humira) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab (Humira) and Biosimilar, with price, sales, revenue and global market share of Adalimumab (Humira) and Biosimilar from 2018 to 2023.
Chapter 3, the Adalimumab (Humira) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab (Humira) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab (Humira) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab (Humira) and Biosimilar.
Chapter 14 and 15, to describe Adalimumab (Humira) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report is a detailed and comprehensive analysis for global Adalimumab (Humira) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Adalimumab (Humira) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adalimumab (Humira) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Adalimumab (Humira) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Syringe
- Pen
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Crohn’s Disease
- Other
- AbbVie
- Eisai
- Cadila Healthcare
- Torrent Pharmaceuticals
- Amgen
- Boehringer Ingelheim
- Novartis
- Samsung Bioepis
- Viatris
- Pfizer
- Fresenius Kabi
- Coherus
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Adalimumab (Humira) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab (Humira) and Biosimilar, with price, sales, revenue and global market share of Adalimumab (Humira) and Biosimilar from 2018 to 2023.
Chapter 3, the Adalimumab (Humira) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab (Humira) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab (Humira) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab (Humira) and Biosimilar.
Chapter 14 and 15, to describe Adalimumab (Humira) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Syringe
1.3.3 Pen
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Adalimumab (Humira) and Biosimilar Market Size & Forecast
1.5.1 Global Adalimumab (Humira) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
2.1.4 AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Recent Developments/Updates
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
2.2.4 Eisai Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Eisai Recent Developments/Updates
2.3 Cadila Healthcare
2.3.1 Cadila Healthcare Details
2.3.2 Cadila Healthcare Major Business
2.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
2.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cadila Healthcare Recent Developments/Updates
2.4 Torrent Pharmaceuticals
2.4.1 Torrent Pharmaceuticals Details
2.4.2 Torrent Pharmaceuticals Major Business
2.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
2.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Torrent Pharmaceuticals Recent Developments/Updates
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business
2.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
2.5.4 Amgen Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amgen Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
2.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
2.7.4 Novartis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments/Updates
2.8 Samsung Bioepis
2.8.1 Samsung Bioepis Details
2.8.2 Samsung Bioepis Major Business
2.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
2.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Samsung Bioepis Recent Developments/Updates
2.9 Viatris
2.9.1 Viatris Details
2.9.2 Viatris Major Business
2.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
2.9.4 Viatris Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Viatris Recent Developments/Updates
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
2.10.4 Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Recent Developments/Updates
2.11 Fresenius Kabi
2.11.1 Fresenius Kabi Details
2.11.2 Fresenius Kabi Major Business
2.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
2.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fresenius Kabi Recent Developments/Updates
2.12 Coherus
2.12.1 Coherus Details
2.12.2 Coherus Major Business
2.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
2.12.4 Coherus Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Coherus Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ADALIMUMAB (HUMIRA) AND BIOSIMILAR BY MANUFACTURER
3.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.5 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
3.5.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
3.5.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region
4.1.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.5 South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Adalimumab (Humira) and Biosimilar Market Size by Country
7.3.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Adalimumab (Humira) and Biosimilar Market Size by Country
8.3.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adalimumab (Humira) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Adalimumab (Humira) and Biosimilar Market Size by Country
10.3.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adalimumab (Humira) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Adalimumab (Humira) and Biosimilar Market Drivers
12.2 Adalimumab (Humira) and Biosimilar Market Restraints
12.3 Adalimumab (Humira) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Adalimumab (Humira) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab (Humira) and Biosimilar
13.3 Adalimumab (Humira) and Biosimilar Production Process
13.4 Adalimumab (Humira) and Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab (Humira) and Biosimilar Typical Distributors
14.3 Adalimumab (Humira) and Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Syringe
1.3.3 Pen
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Adalimumab (Humira) and Biosimilar Market Size & Forecast
1.5.1 Global Adalimumab (Humira) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
2.1.4 AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Recent Developments/Updates
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
2.2.4 Eisai Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Eisai Recent Developments/Updates
2.3 Cadila Healthcare
2.3.1 Cadila Healthcare Details
2.3.2 Cadila Healthcare Major Business
2.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
2.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cadila Healthcare Recent Developments/Updates
2.4 Torrent Pharmaceuticals
2.4.1 Torrent Pharmaceuticals Details
2.4.2 Torrent Pharmaceuticals Major Business
2.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
2.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Torrent Pharmaceuticals Recent Developments/Updates
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business
2.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
2.5.4 Amgen Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amgen Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
2.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
2.7.4 Novartis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments/Updates
2.8 Samsung Bioepis
2.8.1 Samsung Bioepis Details
2.8.2 Samsung Bioepis Major Business
2.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
2.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Samsung Bioepis Recent Developments/Updates
2.9 Viatris
2.9.1 Viatris Details
2.9.2 Viatris Major Business
2.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
2.9.4 Viatris Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Viatris Recent Developments/Updates
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
2.10.4 Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Recent Developments/Updates
2.11 Fresenius Kabi
2.11.1 Fresenius Kabi Details
2.11.2 Fresenius Kabi Major Business
2.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
2.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fresenius Kabi Recent Developments/Updates
2.12 Coherus
2.12.1 Coherus Details
2.12.2 Coherus Major Business
2.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
2.12.4 Coherus Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Coherus Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ADALIMUMAB (HUMIRA) AND BIOSIMILAR BY MANUFACTURER
3.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.5 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
3.5.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
3.5.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region
4.1.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.5 South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Adalimumab (Humira) and Biosimilar Market Size by Country
7.3.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Adalimumab (Humira) and Biosimilar Market Size by Country
8.3.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adalimumab (Humira) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Adalimumab (Humira) and Biosimilar Market Size by Country
10.3.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adalimumab (Humira) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Adalimumab (Humira) and Biosimilar Market Drivers
12.2 Adalimumab (Humira) and Biosimilar Market Restraints
12.3 Adalimumab (Humira) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Adalimumab (Humira) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab (Humira) and Biosimilar
13.3 Adalimumab (Humira) and Biosimilar Production Process
13.4 Adalimumab (Humira) and Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab (Humira) and Biosimilar Typical Distributors
14.3 Adalimumab (Humira) and Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Adalimumab (Humira) and Biosimilar Product and Services
Table 6. AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AbbVie Recent Developments/Updates
Table 8. Eisai Basic Information, Manufacturing Base and Competitors
Table 9. Eisai Major Business
Table 10. Eisai Adalimumab (Humira) and Biosimilar Product and Services
Table 11. Eisai Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Eisai Recent Developments/Updates
Table 13. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 14. Cadila Healthcare Major Business
Table 15. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
Table 16. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Cadila Healthcare Recent Developments/Updates
Table 18. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Torrent Pharmaceuticals Major Business
Table 20. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
Table 21. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Torrent Pharmaceuticals Recent Developments/Updates
Table 23. Amgen Basic Information, Manufacturing Base and Competitors
Table 24. Amgen Major Business
Table 25. Amgen Adalimumab (Humira) and Biosimilar Product and Services
Table 26. Amgen Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Amgen Recent Developments/Updates
Table 28. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 29. Boehringer Ingelheim Major Business
Table 30. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
Table 31. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Boehringer Ingelheim Recent Developments/Updates
Table 33. Novartis Basic Information, Manufacturing Base and Competitors
Table 34. Novartis Major Business
Table 35. Novartis Adalimumab (Humira) and Biosimilar Product and Services
Table 36. Novartis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Novartis Recent Developments/Updates
Table 38. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 39. Samsung Bioepis Major Business
Table 40. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
Table 41. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Samsung Bioepis Recent Developments/Updates
Table 43. Viatris Basic Information, Manufacturing Base and Competitors
Table 44. Viatris Major Business
Table 45. Viatris Adalimumab (Humira) and Biosimilar Product and Services
Table 46. Viatris Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Viatris Recent Developments/Updates
Table 48. Pfizer Basic Information, Manufacturing Base and Competitors
Table 49. Pfizer Major Business
Table 50. Pfizer Adalimumab (Humira) and Biosimilar Product and Services
Table 51. Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Pfizer Recent Developments/Updates
Table 53. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 54. Fresenius Kabi Major Business
Table 55. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
Table 56. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Fresenius Kabi Recent Developments/Updates
Table 58. Coherus Basic Information, Manufacturing Base and Competitors
Table 59. Coherus Major Business
Table 60. Coherus Adalimumab (Humira) and Biosimilar Product and Services
Table 61. Coherus Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Coherus Recent Developments/Updates
Table 63. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Adalimumab (Humira) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Adalimumab (Humira) and Biosimilar Production Site of Key Manufacturer
Table 68. Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
Table 69. Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
Table 70. Adalimumab (Humira) and Biosimilar New Market Entrants and Barriers to Market Entry
Table 71. Adalimumab (Humira) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Adalimumab (Humira) and Biosimilar Raw Material
Table 131. Key Manufacturers of Adalimumab (Humira) and Biosimilar Raw Materials
Table 132. Adalimumab (Humira) and Biosimilar Typical Distributors
Table 133. Adalimumab (Humira) and Biosimilar Typical Customers
Table 1. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Adalimumab (Humira) and Biosimilar Product and Services
Table 6. AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AbbVie Recent Developments/Updates
Table 8. Eisai Basic Information, Manufacturing Base and Competitors
Table 9. Eisai Major Business
Table 10. Eisai Adalimumab (Humira) and Biosimilar Product and Services
Table 11. Eisai Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Eisai Recent Developments/Updates
Table 13. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 14. Cadila Healthcare Major Business
Table 15. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
Table 16. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Cadila Healthcare Recent Developments/Updates
Table 18. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Torrent Pharmaceuticals Major Business
Table 20. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
Table 21. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Torrent Pharmaceuticals Recent Developments/Updates
Table 23. Amgen Basic Information, Manufacturing Base and Competitors
Table 24. Amgen Major Business
Table 25. Amgen Adalimumab (Humira) and Biosimilar Product and Services
Table 26. Amgen Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Amgen Recent Developments/Updates
Table 28. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 29. Boehringer Ingelheim Major Business
Table 30. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
Table 31. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Boehringer Ingelheim Recent Developments/Updates
Table 33. Novartis Basic Information, Manufacturing Base and Competitors
Table 34. Novartis Major Business
Table 35. Novartis Adalimumab (Humira) and Biosimilar Product and Services
Table 36. Novartis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Novartis Recent Developments/Updates
Table 38. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 39. Samsung Bioepis Major Business
Table 40. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
Table 41. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Samsung Bioepis Recent Developments/Updates
Table 43. Viatris Basic Information, Manufacturing Base and Competitors
Table 44. Viatris Major Business
Table 45. Viatris Adalimumab (Humira) and Biosimilar Product and Services
Table 46. Viatris Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Viatris Recent Developments/Updates
Table 48. Pfizer Basic Information, Manufacturing Base and Competitors
Table 49. Pfizer Major Business
Table 50. Pfizer Adalimumab (Humira) and Biosimilar Product and Services
Table 51. Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Pfizer Recent Developments/Updates
Table 53. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 54. Fresenius Kabi Major Business
Table 55. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
Table 56. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Fresenius Kabi Recent Developments/Updates
Table 58. Coherus Basic Information, Manufacturing Base and Competitors
Table 59. Coherus Major Business
Table 60. Coherus Adalimumab (Humira) and Biosimilar Product and Services
Table 61. Coherus Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Coherus Recent Developments/Updates
Table 63. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Adalimumab (Humira) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Adalimumab (Humira) and Biosimilar Production Site of Key Manufacturer
Table 68. Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
Table 69. Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
Table 70. Adalimumab (Humira) and Biosimilar New Market Entrants and Barriers to Market Entry
Table 71. Adalimumab (Humira) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Adalimumab (Humira) and Biosimilar Raw Material
Table 131. Key Manufacturers of Adalimumab (Humira) and Biosimilar Raw Materials
Table 132. Adalimumab (Humira) and Biosimilar Typical Distributors
Table 133. Adalimumab (Humira) and Biosimilar Typical Customers
LIST OF FIGURES
Figure 1. Adalimumab (Humira) and Biosimilar Picture
Figure 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Syringe Examples
Figure 5. Pen Examples
Figure 6. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Ankylosing Spondylitis Examples
Figure 9. Rheumatoid Arthritis Examples
Figure 10. Crohn’s Disease Examples
Figure 11. Other Examples
Figure 12. Global Adalimumab (Humira) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Adalimumab (Humira) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 54. China Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Adalimumab (Humira) and Biosimilar Market Drivers
Figure 75. Adalimumab (Humira) and Biosimilar Market Restraints
Figure 76. Adalimumab (Humira) and Biosimilar Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Adalimumab (Humira) and Biosimilar in 2022
Figure 79. Manufacturing Process Analysis of Adalimumab (Humira) and Biosimilar
Figure 80. Adalimumab (Humira) and Biosimilar Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Adalimumab (Humira) and Biosimilar Picture
Figure 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Syringe Examples
Figure 5. Pen Examples
Figure 6. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Ankylosing Spondylitis Examples
Figure 9. Rheumatoid Arthritis Examples
Figure 10. Crohn’s Disease Examples
Figure 11. Other Examples
Figure 12. Global Adalimumab (Humira) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Adalimumab (Humira) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 54. China Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Adalimumab (Humira) and Biosimilar Market Drivers
Figure 75. Adalimumab (Humira) and Biosimilar Market Restraints
Figure 76. Adalimumab (Humira) and Biosimilar Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Adalimumab (Humira) and Biosimilar in 2022
Figure 79. Manufacturing Process Analysis of Adalimumab (Humira) and Biosimilar
Figure 80. Adalimumab (Humira) and Biosimilar Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
